MD. Criminal Law Code Ann. §  5-405 (2021)
2021 Maryland Statutes|Criminal Law|Title 5 - Controlled Dangerous Substances, Prescriptions, and Other Substances|Subtitle 4 - Schedules|Section 5-405 - Schedule Iv

    (a)    Schedule IV consists of each controlled dangerous substance:        (1)    listed in this section;        (2)    added to Schedule IV by the Department under § 5–202(b) of this title; or        (3)    designated as a Schedule IV controlled dangerous substance by the federal government unless the Department objects under § 5–202(f) of this title.    (b)    Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:        (1)    not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit;        (2)    dextropropoxyphene (alpha–(+)–4–dimethylamino–1, 2–diphenyl–3–methyl–2–propionoxybutane); and        (3)    2–[(dimethylamino)methyl]–1–(3–methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol).    (c)    Substances listed in Schedule IV include a material, compound, mixture, or preparation that contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designations:        (1)    alfaxalone;        (2)    alprazolam;        (3)    barbital;        (4)    brexanolone;        (5)    bromazepam;        (6)    camazepam;        (7)    carisoprodol;        (8)    chloral betaine;        (9)    chloral hydrate;        (10)    chlordiazepoxide;        (11)    clobazam;        (12)    clonazepam;        (13)    clorazepate;        (14)    clotiazepam;        (15)    cloxazolam;        (16)    delorazepam;        (17)    diazepam;        (18)    dichloralphenazone;        (19)    estazolam;        (20)    ethchlorvynol;        (21)    ethinamate;        (22)    ethyl loflazepate;        (23)    fludiazepam;        (24)    flunitrazepam;        (25)    flurazepam;        (26)    fospropofol;        (27)    halazepam;        (28)    haloxazolam;        (29)    ketazolam;        (30)    loprazolam;        (31)    lorazepam;        (32)    lormetazepam;        (33)    mebutamate;        (34)    medazepam;        (35)    meprobamate;        (36)    methohexital;        (37)    methylphenobarbital (mephobarbital);        (38)    midazolam;        (39)    nimetazepam;        (40)    nitrazepam;        (41)    nordiazepam;        (42)    oxazepam;        (43)    oxazolam;        (44)    paraldehyde;        (45)    petrichloral;        (46)    phenobarbital;        (47)    pinazepam;        (48)    prazepam;        (49)    quazepam;        (50)    suvorexant (Belsomra);        (51)    temazepam;        (52)    tetrazepam;        (53)    triazolam;        (54)    zaleplon (Sonata);        (55)    zolpidem (Ambien); and        (56)    zopiclone (Lunesta).    (d)    Substances listed in Schedule IV include:        (1)    a material, compound, mixture, or preparation that contains fenfluramine; and        (2)    if its existence is possible:            (i)    a salt of fenfluramine;            (ii)    an optical, position, or geometric isomer of fenfluramine, including dexfenfluramine; and            (iii)    a salt of an isomer of fenfluramine.    (e)    Substances listed in Schedule IV include:        (1)    a material, compound, mixture, or preparation that contains lorcaserin; and        (2)    if its existence is possible:            (i)    a salt of lorcaserin;            (ii)    an optical, position, or geometric isomer of lorcaserin; and            (iii)    a salt of an isomer of lorcaserin.    (f)    Substances listed in Schedule IV include a material, compound, mixture, or preparation that contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:        (1)    cathine ((+)–norpseudoephedrine);        (2)    diethylpropion;        (3)    fencamfamin;        (4)    fenproporex;        (5)    mazindol;        (6)    mefenorex;        (7)    modafinil;        (8)    pemoline, including organometallic complexes and their chelates;        (9)    phentermine;        (10)    pipradrol;        (11)    sibutramine;        (12)    solriamfetol (2–amino–3–phenylpropyl carbamate; benzenepropanol, beta–amino–, carbamate (ester)); and        (13)    SPA ((–)–1–dimethylamino– 1,2–diphenylethane).    (g)    Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances, including its salts:        (1)    pentazocine;        (2)    butorphanol (including its optical isomers); and        (3)    eluxadoline (5–[[[(2S)–2–amino–3–[4–aminocarbonyl)–2, 6–dimethylphenyl]–1–oxopropyl][(1S)–1–(4–phenyl–1H–imidazol–2–yl)ethyl]amino]methyl]–2–methoxybenzoic acid) (including its optical isomers) and its salts, isomers, and salts of isomers.    (h)    By regulation, the Department may exempt from this section a compound, mixture, or preparation that contains a depressant substance listed in subsection (b) of this section if:        (1)    the compound, mixture, or preparation contains an active medicinal ingredient that does not have a depressant effect on the central nervous system; and        (2)    the admixtures are included in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances that have a depressant effect on the central nervous system.    (i)    The Department may not add a substance to Schedule IV under § 5–202 of this title unless the Department finds that:        (1)    the substance has a low potential for abuse relative to the substances listed in Schedule III;        (2)    the substance has currently accepted medical use in treatment in the United States; and        (3)    abuse of the substance may lead to limited physical dependence or psychological dependence relative to the substances in Schedule III.